Revolution Medicines, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Revolution Medicines reports significant clinical advancements for its RAS(ON) inhibitor pipeline, including multiple FDA Breakthrough Therapy Designations, alongside increased R&D expenses and a net loss of $1.13 billion for 2025.
NASDAQ
Revolution Medicines' 10-K filing summarizes the company's financial performance and clinical development progress in 2024, focusing on its RAS(ON) inhibitor programs.
NASDAQ
Revolution Medicines provides a detailed description of its common stock, public warrants, private placement warrants, and earn-out shares in a recent SEC filing.